Tuesday, April 4, 2017

B2B Cannabis E-Commerce Platform LeafLink Raises $3 Million Seed Round Led by Lerer Hippeau

B2B Cannabis E-Commerce Platform LeafLink Raises $3 Million Seed Round Led by Lerer Hippeau

Other Strategic Investors Including Casa Verde Capital Participate to Advance the "Amazon" for Dispensaries


NEW YORK - April 3, 2017 (Investorideas.com Newswire) The B2B cannabis e-commerce platform LeafLink today announces it has closed a $3 Million seed round led by New York's Lerer Hippeau Ventures, a tech-focused venture fund with early investments in companies such as Oscar Health, Casper, Warby Parker, Venmo, and Buzzfeed. Additional participants include strategic investors from both inside and outside the cannabis space, including Casa Verde Capital, Phyto Partners, Wisdom VC, and Wan Li Zhu and Paul Ciriello of Fairhaven Capital. LeafLink, which is currently live in Colorado and Washington, will use the funds to expand its marketplace for cannabis brands and dispensaries into newly legal markets.
Cannabis retailers previously managed their ordering process through emails, texts, and phone calls with a decentralized web of cannabis flower, edible, concentrate, and topical vendors. With LeafLink, they can place all of their orders in one legally compliant shopping experience. The vendors then manage their incoming orders using the platform's suite of business tools, including a CRM, data reporting, order status tracking, and fulfillment queue.
"As the legal cannabis space is new and growing rapidly, we are not disrupting an industry, but defining it," Ryan G. Smith, co-founder and CEO of LeafLink, said. "At LeafLink, our goal is to empower cannabis business owners with a B2B marketplace and supporting tools that will give them the efficiency they need to grow."
Since launching in Colorado in March and in Washington in October, 800 dispensaries have joined LeafLink and placed orders for over 100 cannabis product brands, including Incredibles, CannaPunch, Dixie Elixirs, Wana Brands, ZOOTS, Apothecanna, and Keef Cola. At present, the company is doing $65 Million in orders through the platform on an annual basis.
With the seed funding, the company plans to launch in additional states with legal recreational and medical cannabis programs, including California, Nevada, and Oregon, beginning this spring. Smith said, "LeafLink's entry into these markets is an enormous opportunity to build a tech-first industry that will serve as a model for other states, and for other industries outside cannabis."
LeafLink's seed round marks the first investment in the cannabis space for Lerer Hippeau. "Legal cannabis is creating a massive new market from scratch," Eric Hippeau, Managing Partner of Lerer Hippeau Ventures, said. "LeafLink's platform links brands and retailers in a seamless marketplace that is vital to the growth of the industry's try. We are impressed by the vision of LeafLink's founders and look forward to supporting their growth."
Karan Wadhera of Casa Verde Capital said, "the cannabis industry is in its infancy and our mission is to support those businesses that will set the standard for how the community operates. We believe LeafLink is doing just that in establishing itself as a critical component for brands and retailers across the country."
About LeafLink:
LeafLink is the leading B2B platform for orders, sales and relationship management for cannabis product brands and retailers. It is an ancillary technology business that does not touch, buy or sell cannabis. With offices in New York, Denver and Seattle, the company launched in March 2016 and is currently live in Colorado and Washington. To date, the company has raised over $4M in capital, including a previous angel round of $1M closed in December 2015.
Media Contact:
Claire Moloney
153178@email4pr.com
5162368382

Like Marijuana Stocks? View our Marijuana / Hemp Stocks Directory

Join our Group on Linkedin - Marijuana / Hemp Stocks - News and Trends in Green Investing

Global Cannabis Investing - features Investor Ideas Cannabis news

Get News Alerts on Marijuana Stocks




Watch the 420 Cannabis Investor video

 

More Info:



This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Medical Marijuana Stock News: Marapharm Ventures Inc. (OTCQB: $MRPHF) (CSE: $MDM) Kelowna, B.C. Announces a Laboratory for Research and Development of Marijuana for its Washington Property

Medical Marijuana Stock News: Marapharm Ventures Inc. (OTCQB: $MRPHF) (CSE: $MDM) Kelowna, B.C. Announces a Laboratory for Research and Development of Marijuana for its Washington Property


KELOWNA, British Columbia - April 4, 2017 (Investorideas.com Newswire) Marapharm (OTCQB: MRPHF) (CSE: MDM) (FSE: 2M0) is pleased to announce that it has entered into an agreement with AlphaPheno Inc. ("Alpha") of Washington state to build a laboratory on the 13.6-acre-site of Marapharm's property. Alpha, in conjunction with Veritas Pharma Inc., an emerging discovery and IP development company, will enter into a joint venture arrangement for the research and development ("R&D") business. Alpha holds a Tier 3 cultivation and processing license and therefore is permitted to apply for and hold an R&D license. With an extensive list of cannabis genetics and existing cultivation space, Alpha is applying for a marijuana research license to leverage the synergy with Veritas in the U.S. market. The agreement is conditional on acceptance of the application. The license will provide the holder with the ability to produce, process, and possess marijuana to test chemical potency and composition levels, to conduct clinical investigations of marijuana-derived drug products, to conduct research on the efficacy and safety of administering marijuana as part of medical treatment, and to conduct genomic and or agriculture research. Veritas will provide the R&D thesis, programs, equipment, and laboratory standards and protocol for a focused R&D approach. Veritas will also determine the key qualified personnel required to execute these programs. A new laboratory will be constructed within Marapharm's buildings, which are occupied by Alpha.
"The R&D laboratory will be a welcome addition to the cannabis campus and is a reason for other cannabis businesses to look to us for a facility. Veritas, (VRT and VRTHF), is a public company, of which Marapharm owns 15 million shares, so entering into a joint venture with Veritas represents another level of commitment", said Linda Sampson, Marapharm's CEO.
ABOUT MARAPHARM VENTURES INC.
Construction photos and videos can be accessed through the Marapharm website. Marapharm's common shares are publicly traded in Canada, under the ticker symbol "MDM" on the Canadian Securities Exchange, and in the United States, under the ticker symbol "MRPHF" on the OTCQB, and in Europe, under the ticker symbol "2M0" on the FSE.
Marapharm has 300,000 square feet of medical marijuana licenses for its land and facilities in WA and NV. About two and a half years ago, Marapharm applied in Canada to Health Canada for a MMPR (production and sales) license and has passed the necessary security clearances. The application is currently in the in-depth screening process. In September 2016, Health Canada contacted Marapharm with a provision to amend its application to allow for the new regulations, ACMPR.
Additional information on the operations or financial results of Marapharm are included in reports on file with applicable securities regulatory authorities and may be accessed through the CSE website (http://www.thecse.com), the OTC website (http://www.otcmarkets.com), and the SEDAR website (http://www.sedar.com) under the profile for Marapharm Ventures Inc.
STOCK EXCHANGES:
Neither the CSE, the FSE nor the OTCQB® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQB® accepts responsibility for the adequacy or accuracy of this release.
FORWARD - LOOKING STATEMENTS:
Certain statements contained in this news release constitute forward-looking statements, specifically with respect to the proposed joint venture arrangement with AlphaPheno Inc. and Veritas Pharma Inc. and the construction of a laboratory on Marapharm's Washington property. The use of any of the words "anticipate", "continue", "estimate", "expect", 'may", "will", "project", "should", 'believe", and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon. Specifically, Marapharm may not be able to complete the construction of the laboratory on the terms proposed and there is no assurance the joint venture arrangement will proceed to completion or be successful.
FOR FURTHER INFORMATION:
http://www.marapharm.com or Linda Sampson, CEO, +1-778-583-4476 info@marapharm.com
SOURCE Marapharm Ventures Inc.

Like Marijuana Stocks? View our Marijuana / Hemp Stocks Directory

Join our Group on Linkedin - Marijuana / Hemp Stocks - News and Trends in Green Investing

Global Cannabis Investing - features Investor Ideas Cannabis news

Get News Alerts on Marijuana Stocks




Watch the 420 Cannabis Investor video

 

More Info:




This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Cannabis News: MagicalButter.com Sets Safety Standard With Creation of Edibles Molds

Cannabis News: MagicalButter.com Sets Safety Standard With Creation of Edibles Molds
21UP™ Edible Mold Urges Industry Self-Regulation

PORT RICHEY, FLA - April 4, 2017 (Investorideas.com Newswire) MagicalButter.com, the industry leader in herbal extraction machines, has created the first-ever silicone molds specifically made to distinguish the difference between medicated items meant for adults and candy for children. These molds make it easy for those age 21UP™, to ingest medical cannabis in the popular form of gummies, with their family and friend's safety in mind. The industry-changing 21UP molds will be used by dispensaries, pharmacies, and consumers within the medical cannabis community to make edibles.
"One of the major problems in the cannabis market is the indirect marketing of candy meant for adults to children," says Garyn Angel, founder and CEO of MagicalButter.com. "By differentiating medicated edibles from regular gummy bears with a 21UP label, minors will be less likely to accidentally ingest a medical marijuana edible."
Similar to the Colorado molds by the Colorado Marijuana Enforcement Division, the 21UP mold features the saying, "21UP" to signify that the candy is only meant for adults and those of age. To encourage broad acceptance of this protective measure, MagicalButter.com offers the use of their trademarked 21UP logo to any company making medicated products such as gummies, hard candies, lollipops, etc. at a 3 percent royalty and 10 percent net profit, plus production cost, ensuring the 21UP molds are the least expensive to buy and manufacture.
"By promoting a low cost, we hope to encourage the self-regulation the cannabis industry needs," says Angel. "MagicalButter is excited to work with other cannabis-industry leaders to continue identifying best practices and guidelines to pave the way for both medical and recreational use"
All packaging proudly bears the label "Made in USA" and will also be available on MagicalButter.com at a retail price of 2 for $9.95.
ABOUT GARYN ANGEL
Garyn Angel is an award-winning financier, inventor, and philanthropist from Port Richey, Florida. Prior to becoming a renowned expert in the commercial aspects of cannabis (cannabusiness), he had a successful career as one of the nation's top financial advisors. That career path allowed him to develop a very diverse business background.
In 2011, fueled by the desire to help an extremely ill friend, Angel developed the first self-contained herbal extraction appliance for the home kitchen. The device processes cannabis into an ingestible form that eliminates the toxicity of smoke and maintains consistent quality. His friend's stunning results with the machine eventually led Angel to launch MagicalButter.com and begin to advocate international cannabis law reform. In 2014 he was selected to the exclusive CNBC NEXT List of global business visionaries for his work in the field of legal marijuana. Angel was joined on the list by influential leaders in other fields including the CEOs of Apple, GM, Google, MasterCard, Netflix, Tesla, and Twitter. He continues to use his knowledge and experience to help bring the benefits of cannabis to the world.
For all partnership and press inquiries regarding MagicalButter, please contact:
Elyse Bender-Segall
PR Revolution
elyse@prrevolution.com
(516) 901-9095
Kelsey Churgin
PR Revolution
Office: 973.695.1110
Fax: 855.715.6300
kelsey@prrevolution.com
prrevolution.com

Like Marijuana Stocks? View our Marijuana / Hemp Stocks Directory

Join our Group on Linkedin - Marijuana / Hemp Stocks - News and Trends in Green Investing

Global Cannabis Investing - features Investor Ideas Cannabis news

Get News Alerts on Marijuana Stocks




Watch the 420 Cannabis Investor video

 

More Info:



This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Monday, April 3, 2017

#Cannabis Testing Market to Reach $1.4 Billion by 2021 - Driven by Growing Number of Cannabis Testing Laboratories

#Cannabis Testing Market to Reach $1.4 Billion by 2021 - Driven by Growing Number of Cannabis Testing Laboratories

DUBLIN - March 31, 2017 (Investorideas.com Newswire) Research and Markets has announced the addition of the "Cannabis Testing Market - Global Forecast to 2021" report to their offering.
The global cannabis testing market is expected to reach USD 1,416.3 Million by 2021 from USD 822.0 Million in 2016, at a CAGR of 11.5% during the forecast period (2016-2021).
The growth in this market is mainly driven by factors such as legalization of medical cannabis, coupled with the growing number of cannabis testing laboratories (specifically in the U.S.); growing adoption of LIMS in cannabis testing laboratories; and increasing awareness through conferences, symposia, and workshops. On the other hand, the high cost of analytical instruments, presence of alternative technologies, and dearth of skilled professionals are some of the major factors that are expected to restrain the growth of this market in the coming years.
This report segments the cannabis testing market into cannabis testing products (analytical instruments and consumables) & software (Cannabis LIMS), cannabis testing services, end users, and regions. On the basis of products, the market is broadly categorized into two segments, namely, analytical instruments and consumables. The consumables segment is expected to grow at the highest CAGR during the forecast period owing to their recurring requirement and repetitive usage.
Companies Mentioned:
  • AB Sciex LLC
  • Accelerated Technology Laboratories, Inc.
  • Agilent Technologies, Inc.
  • Digipath, Inc.
  • Millipore Sigma
  • Perkinelmer, Inc.
  • Pharmlabs LLC
  • Restek Corporation
  • SC (Science of Cannabis) Laboratories, Inc.
  • Shimadzu Corporation
  • Steep Hill Halent Laboratories, Inc.
  • Waters Corporation
Key Topics Covered:
  • Introduction
  • Research Methodology
  • Executive Summary
  • Premium Insights
  • Market Overview
  • Industry Insights
  • Cannabis Testing Market, By Product and Software
  • Cannabis Testing Services Market, By Type
  • Cannabis Testing Market,By End User
  • Cannabis Testing Market, By Region
  • Competitive Landscape
  • Company Profiles
  • Appendix
For more information about this report visit http://www.researchandmarkets.com/research/nzcslq/cannabis_testing
Media Contact:
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Like Marijuana Stocks? View our Marijuana / Hemp Stocks Directory
Global Cannabis Investing - features Investor Ideas Cannabis news



Watch the 420 Cannabis Investor video
 

More Info:

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.


Cannabis Stock News: General Cannabis (OTCQB: $CANN) Announces 2016 Fourth Quarter and Year-End Results

Cannabis Stock News: General Cannabis (OTCQB: $CANN) Announces 2016 Fourth Quarter and Year-End Results
Year-Over-Year Revenue Growth of 69 Percent Recorded

DENVER - March 31, 2017 (Investorideas.com Newswire) General Cannabis Corp (OTCQB: CANN), the comprehensive resource to the regulated cannabis industry, today announced financial results for the year and quarter ended December 31, 2016.
"Our year-over-year revenue growth of 69 percent and quarter-over-quarter revenue growth of 13 percent comes from both organic growth and a full year of expanding the businesses we launched in 2015," said Robert Frichtel, Chief Executive Officer of General Cannabis. "With 28 states and the District of Columbia now having legalized medical marijuana, of which eight states also legalized recreational use, there is a tremendous opportunity for us to significantly expand our business in 2017."
"We also have been focusing on managing our operating costs and expenses, and incurred only an 11 percent year-over-year increase, even as our revenue grew" Frichtel added. "We have demonstrated our ability to acquire and develop substantial companies that serve this rapidly expanding industry."
Our full results can be found at www.generalcann.com/sec-filings/.
Financial Highlights
The following tables summarize our 2016 year-end and fourth quarter results:


The significant increase in the "Other expense" category for the quarter and year ended December 31, 2016, was due almost entirely to non-cash expenses associated with warrants issued with our new debt and retiring our old debt. For more information on these transactions, see Capital Raise below.
"I am excited by the recapitalization and growth of our business in 2016," said Michael Feinsod, Executive Chairman of General Cannabis. "To date, warrant exercises from the recapitalization have resulted in cash of $1,160,000 and principal reduction of $670,000. We are well-positioned to acquire additional businesses and assets in 2017, as well as expand into new markets. We continue to prove that we have one of the strongest platform in the industry and are poised for continued growth."
Current Business Trends and 2017 Outlook
  • We expect to make more acquisitions in 2017. We are currently evaluating opportunities in all areas of regulated cannabis. We remain well capitalized and positioned to help businesses expand rapidly.
  • The trend towards state regulated marijuana is accelerating. All of our businesses continue to enjoy significant demand and we are expanding our Iron Protection Group into additional states in 2017.
  • We are already working with clients in California, Maryland, Nevada and Pennsylvania as they respond to new voter mandates. Next Big Crop has the skills and experience to assist operators and investors as they take advantage of regulated cannabis expansion into 28 states.
  • We expect continued growth in Chiefton as we roll out our marijuana-specific marketing/advertising agency format.
  • GC Supply had a strong quarter and is poised to continue this relationship-based service to our clients in existing and new markets.
  • We anticipate rolling out new internally started initiatives in 2017: ◦Next Big Crop's Management Service program is accelerating. We plan to continue our active business of helping licensed producers build, open, and manage cultivation sites and retail locations, with the most cutting-edge technologies available.
    • Canna Runner, our cash transport business, anticipates significant growth in 2017, as Colorado Transport Rules go into effect. This IPG subdivision already provides cash transport for numerous Colorado dispensaries.
    • A banking solution. Using our corporate headquarters ("The Greenhouse"), and its existing hard assets, we are remodeling the facility to provide a turnkey solution for a banking operator seeking to service the regulated marijuana industry in a standalone facility.
Capital Raise
In September, we completed a $3.00 million debt refinancing. We received $2.45 million of cash for issuing the 12% Notes. $550,000 of our long-term debt was converted into 12% Notes, and we used some of the proceeds to retire all of our other long-term debt, which totaled approximately $912,000. The new capital provides General Cannabis the working capital necessary to actively pursue new acquisitions and investment opportunities. As of March 30, 2017, 3.3 million warrants have been exercised, for which we have received cash proceeds of approximately $1.16 million and a reduction in 12% Note principal of approximately $670,000. The remaining 5.7 million of unexercised warrants issued with the debt offering could provide up to approximately $2.98 million of additional proceeds if fully exercised on a cash basis. A summary of the transaction is as follows:
  • $3.00 million of 12% notes were issued on September 21, 2016.
  • Cash interest is payable quarterly.
  • The notes mature on September 21, 2018.
  • In connection with the issuance of the Notes, 9 million warrants to purchase common stock were issued.
  • If the company's common stock closes above $5 for 10 consecutive days, the Company may call the warrants, giving the holder 30 days to exercise.
  • The warrants expire on September 21, 2019.
  • The warrants have certain anti-dilution and re-pricing provisions. The latter require us, under GAAP, to record changes in the fair value of the warrants as income or expense, which may have a significant non-cash impact to our results of operations.
About General Cannabis Corp
General Cannabis Corp is the all-in-one resource for the highest quality service providers available to the regulated cannabis industry. We are a trusted partner to the cultivation, production and retail sides of the cannabis business. We do this through a combination of strong operating divisions such as security, marketing, operational consulting and products, real estate and financing. As a synergistic holding company, our divisions are able to leverage the strengths of each other, as well as a larger balance sheet, to succeed. Our website address is www.generalcann.com.
Forward-looking Statements
This presentation contains forward-looking statements that relate to future events or General Cannabis' future performance or financial condition. Such statements include statements regarding the opportunity for us to significantly expand our business; statements that we are well-positioned to acquire additional businesses or expand into new markets; statements that we expect to make more acquisitions; statements that we expect continued growth; statements that we are poised to continue relationship-based service; and statements that we plan to continue our active business of helping licensed producers. Any statements that are not statements of historical fact, such as the statements above and including statements containing the words "plans," "anticipates," "expects" and similar expressions, should also be considered to be forward-looking statements. These forward-looking statements are not guarantees of future performance, condition or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as result of a number of factors, including those described from time to time in General Cannabis' filings with the Securities and Exchange Commission. General Cannabis undertakes no duty to update any forward-looking statements made herein.

Like Marijuana Stocks? View our Marijuana / Hemp Stocks Directory
Global Cannabis Investing - features Investor Ideas Cannabis news



Watch the 420 Cannabis Investor video

 

More Info:

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.